Chronic-phase HIV and simian immunodeficiency virus (SIV) replication is reduced by as much as 10,000-fold in elite controllers (ECs) compared with typical progressors (TPs), but sufficient viral replication persists in EC tissues to allow viral sequence evolution and induce excess immune activation. Here we show that productive SIV infection in rhesus monkey ECs, but not TPs, is markedly restricted to CD4 + follicular helper T (T FH ) cells, suggesting that these EC monkeys' highly effective SIV-specific CD8 + T cells can effectively clear productive SIV infection from extrafollicular sites, but their relative exclusion from B cell follicles prevents their elimination of productively infected T FH cells. CD8 + lymphocyte depletion in EC monkeys resulted in a dramatic re-distribution of productive SIV infection to non-T FH cells, with restriction of productive infection to T FH cells resuming upon CD8 + T cell recovery. Thus, B cell follicles constitute 'sanctuaries' for persistent SIV replication in the presence of potent anti-viral CD8 + T cell responses, potentially complicating efforts to cure HIV infection with therapeutic vaccination or T cell immunotherapy. 
a r t i c l e s HIV and its nonhuman-primate counterpart, SIV, use both specific genetic mechanisms and extraordinary genetic malleability and functional plasticity to either evade or escape innate and adaptive immunity 1,2 . Indeed, the vast majority of infected individuals experience persistent high-level viral replication that, in the absence of combination anti-retroviral therapy (cART), leads to AIDS in susceptible species (humans and Asian macaques) 3 . However, rare individuals known as elite controllers (<1% of HIV-1-infected humans) are able to mount highly effective immune responses that suppress viral replication to very low levels, as much as 10,000-fold lower than typical HIV or SIV infections 4, 5 . Given the ability of HIV and SIV to establish a stable, latent viral reservoir early in infection 6 and the inability of the adaptive immune system to recognize latently infected cells (e.g., cells with integrated viral genomes and no viral gene expression), it is not surprising that even the highly effective immune responses of ECs fail to completely clear HIV or SIV infection. However, it is noteworthy that even these uniquely potent immune responses are not entirely effective at suppressing ongoing cycles of viral replication. Ultrasensitive analysis reveals detectable plasma virus in most (if not all) ECs at levels that are, on average, higher than those in individuals with infection suppressed by optimal cART 7, 8 . Furthermore, recovery of replication-competent HIV from CD4 + T cells of EC subjects is reduced by cART and rebounds with cART cessation 9 , and viral sequence analysis indicates that viral replication in ECs is high enough to allow for viral sequence evolution [10] [11] [12] . ECs also manifest higher levels of systemic immune activation than uninfected individuals 13 , and this excess immune activation can be reduced by cART 14 . Taken together, these findings provide compelling evidence of persistent, low-level productive infection in EC subjects.
Highly effective virus-specific CD8 + T cell responses targeting functionally constrained epitopes, typically associated with protective major histocompatibility complex class I (MHC-I) alleles, are thought to be responsible for many, if not most, instances of elite HIV and SIV control 4, 5, [15] [16] [17] [18] . The observation that in vivo CD8 + lymphocyte depletion of monkey ECs is associated with a rapid upsurge in SIV replication 19 , the documentation of immune evolution in ECs 10, 12 , and the ability to isolate replication-competent HIV from human ECs 20 all strongly suggest that elite control typically reflects continuous CD8 + T cell-mediated containment of replication-competent virus. If this conclusion is correct, then the ongoing low-level productive infection must somehow escape these highly effective CD8 + T cell responses. We identified a possible clue to the mechanism of this escape in a previous study of live attenuated SIV vaccines (LAV) in rhesus monkeys. In that study we demonstrated that SIV-specific T cell responses, which were capable of completely protecting the LAV-vaccinated monkeys from highly pathogenic SIV challenge, were continuously maintained by highly restricted LAV replication occurring within the phenotypically distinct CD4 + T FH cell population found in secondary lymphoid tissues 21 . Because most CD8 + effector T cells, including HIV-and SIV-specific CD8 + T cells, lack the appropriate chemokine receptors for B cell follicle entry and are therefore excluded from B cell follicles [22] [23] [24] [25] [26] , these observations imply that LAV-infected T FH cells might avoid elimination by the highly effective SIV-specific CD8 + T cells that they themselves elicit and maintain because of their location within a B cell follicle sanctuary 27 . Indeed, it has been hypothesized that CD8 + T cell exclusion from B cell follicles provides this site with an 'immune privilege' that, along with infection-associated expansion of CD4 + T FH cells, accounts for the high levels of CD4 + T FH cell targeting by HIV and SIV observed in progressive infection [28] [29] [30] [31] [32] [33] .
In this study, we used SIV infection of Indian rhesus macaques to experimentally assess whether this hypothesized B cell follicular immune privilege constitutes a substantial barrier to CD8 + T cellmediated suppression or clearance of productive lentiviral infection, as well as to determine whether this mechanism might account for the persistence of productive SIV infection in cases of elite control. Our data demonstrate that with greater immunologic control, productive SIV infection becomes progressively restricted to CD4 + T FH cells within B cell follicles, and that this restriction is abruptly abrogated with CD8 + lymphocyte depletion, but returns with CD8 + T cell recovery. We also demonstrate preferential B cell follicular localization of residual, productive SIV infection in SIV + monkeys with long-term, fully suppressive cART. Taken together, these data show that productive SIV infection within resident intrafollicular CD4 + T FH cells is substantially shielded from CD8 + T cell-mediated suppression or clearance, and that the B cell follicle sanctuary this shielding implies will likely constitute a barrier to CD8 + T cell-mediated eradication or functional cure of HIV infection.
RESULTS

Immune control restricts productive SIV infection to T FH cells
Although CD4 + T FH cells have been shown to constitute a major and often disproportionate component of the productively HIV-and SIVinfected cell population during chronic-phase infection, it is unclear whether preferential viral targeting of this subset is based on (1) an enhanced susceptibility of CD4 + T FH cells to infection, (2) a longer intrinsic lifespan of infected CD4 + T FH cells, (3) location of T FH cells in a particularly conducive environment for productive infection, (4) the relative expansion of CD4 + T FH versus non-T FH cells in progressive infection, or (5) preferential shielding of productively infected CD4 + T FH cells from immune elimination [29] [30] [31] [32] [33] . To address this question, we used a semi-quantitative coculture assay (see Methods) to determine frequencies of cells harboring replication-competent virus within sorted CD4 + T FH and non-T FH memory T cells from lymph nodes (LNs) of four rhesus monkeys over the course of controlled LAV (nefdeleted SIV mac239 ) or progressive wild-type (WT) SIV mac239 infection. CD4 + T FH cells, delineated by high co-expression of the cell-surface markers PD-1 and CD200 on CD4 + CD95 high memory cells 21, 34 , were compared with non-T FH CD4 + memory T cells that lacked PD-1 and CD200 expression completely (PD-1 neg CD200 neg ) or expressed these markers at a low level (PD-1 dim CD200 dim ; Supplementary Figs. 1 and 2). During acute LAV infection and all phases of progressive WT SIV infection, replication-competent virus was readily isolated from both CD4 + T FH and non-T FH memory T cells (Fig. 1a-c and Supplementary Fig. 3 ). However, after the establishment of immunologic (primarily CD8 + T cell-mediated) control of LAV replication ( Fig. 1a; approximately day 56 post infection), replication-competent virus was isolated only from T FH cells (Fig. 1c) . These data suggest that the restricted localization of replication-competent LAV to CD4 + T FH cells in the chronic phase of LAV infection noted in our previous report 21 , was due to the development of effective CD8 + T cells that preferentially controlled LAV replication in the T cell zone of the LN paracortex relative to the B cell follicles.
To further explore this differential viral control in LN paracortex versus B cell follicles, and ascertain its applicability to immune control of pathogenic WT SIV infection, we compared the frequency of cells harboring replication-competent SIV by coculture assay, and the levels of SIV DNA and RNA by quantitative PCR and RT-PCR, respectively, in CD4 + T FH and non-T FH memory cells isolated from the LNs of 27 rhesus monkeys chronically infected with either WT SIV mac239 or SIV mac251 . These monkeys included ten ECs (plasma viral set point ≤ 600 copies per milliliter), seven semi-controllers (plasma viral set point between 1,900 and 35,000 copies per milliliter), and ten TPs (plasma viral set points ≥ 85,000 copies per milliliter) (Supplementary Table 1 ). The frequency of T FH cells within the overall LN CD4 + memory T cell populations of these monkeys reflected their virologic status with EC monkeys manifesting median T FH cell frequencies of 5% (only slightly higher than uninfected monkeys), semi-controllers 10%, and TPs 27% (Fig. 2a,b) . Notably, and in keeping with findings in LAV-infected monkeys, monkeys with elite control of WT SIV showed exquisite restriction of replicationcompetent virus to their very minor population of CD4 + T FH Fig. 3 ). npg a r t i c l e s population in LN, the latter including both the PD-1 neg /CD200 neg and PD-1 dim /CD200 dim subsets (Fig. 2c,d ). Analysis of spleen cells from an EC monkey showed an identical distribution of replicationcompetent SIV among PD-1/CD200-defined CD4 + memory T cell subsets ( Supplementary Fig. 4) , suggesting that the restriction of productive SIV infection to CD4 + T FH cells is common to all secondary lymphoid tissues in EC monkeys. In contrast, the frequencies of cells containing replication-competent SIV were similar in CD4 + T FH and non-T FH memory T cell subsets in both LNs and spleen from TP monkeys, whereas semi-controller monkeys were intermediate, showing a variable degree of preferential, but not exclusive, localization of replication-competent SIV to CD4 + T FH cells compared with non-T FH cells in both LNs and spleen ( Fig. 2c and Supplementary Fig. 4 ). Quantification of cell-associated SIV RNA in CD4 + T FH and non-T FH memory T cells from these same monkeys confirmed these results, showing significantly higher SIV RNA content in CD4 + T FH cells compared with CD4 + non-T FH memory cells in ECs and in semicontrollers, but no difference in the SIV RNA content in CD4 + T FH cells versus non-T FH memory cells in TP monkeys (Fig. 2e) . These data demonstrate a restriction of productive SIV to CD4 + T FH cells in the presence of immune control, but not in its absence. Notably, levels of cell-associated SIV DNA were only very modestly enriched in CD4 + T FH cells compared with CD4 + non-T FH memory cells in both ECs and semi-controllers (Fig. 2f) , suggesting that the mechanism maintaining preferential T FH cell localization of replication-competent SIV operates primarily, if not exclusively, on productively SIV-infected (SIV antigen-expressing) CD4 + T cells, as would be expected for a CD8 + T cell-mediated process.
Although we validated the phenotypic criteria used to classify and sort CD4 + T FH cells versus non-T FH cells by demonstrating that PD-1 high CD200 high CD4 + T cells are exquisitely restricted to B cell follicles ( Supplementary Fig. 2) , we confirmed the immune control-associated restriction of productive SIV infection to histologically-defined B cell follicular structures in LNs from EC monkeys using RNAscope in situ hybridization and combined, conventional in situ hybridization and immunofluorescence analysis ( Fig. 3; Supplementary Figs . 5 and 6). Productively SIV-infected T FH cells were differentiated from follicular dendritic cell-bound virions by well-described morphologic criteria 31, 35 . Consistent with the cell sorting-based assays, we found that a median of 95% of productively SIV-infected cells within Friedman test determined the significance of overall differences in replication-competent SIV among the PD-1-and CD200-defined CD4 + memory T cell subsets (P values shown; NS, not significant). The Wilcoxon signed-rank test was used for pairwise analysis when the Friedman P value was <0.05 (brackets indicate Wilcoxon signed-rank test, P < 0.05). (e,f) Comparison of cell-associated SIV RNA (e) and DNA (f) levels in the same LN CD4 + memory T cell subsets (n = 7-10 for all groups), with statistical analysis as described in d. the LNs of EC monkeys were localized within B cell follicles (from which CD8 + T cells were largely excluded), whereas in TP monkeys, over half of productively SIV-infected cells were found in the CD8 + T cell-rich paracortex (the latter observation in agreement with our previous study 31 ). Thus, with three different assays of productive SIV infection-frequencies of cells with replication-competent SIV within sorted cell populations, levels of SIV RNA and DNA within sorted cell populations, and anatomic distribution of SIV RNA + cells by in situ analysis -we find a marked association between immune control of infection (as reflected by plasma viral set points) and restriction of productive SIV infection to CD4 + T FH cells.
CD8 + T cells restrict productive SIV infection to T FH cells in ECs
Taken together, these data suggest that the potent SIV-specific CD8 + T cell responses responsible for elite SIV control in rhesus monkeys effectively clear productive SIV infection from the paracortical T cell zones of secondary lymphoid tissues, but are unable to completely suppress SIV replication in the CD4 + T FH cells within B cell follicles. To further test this hypothesis, we monitored the distribution of both replication-competent SIV and SIV RNA and DNA in seven EC monkeys (Supplementary Table 1 ) after transient in vivo CD8 + lymphocyte depletion with the CD8-α-specific monoclonal antibody (mAb) M-T807R1 (Fig. 4) . As expected, mAb M-T807R1 administration completely depleted CD8 + T cells, including SIV-specific CD8 + T cells, from blood and LNs by day 10 after treatment, with partial recovery by day 21 and near-maximal recovery by day 35 (Fig. 4a,b) . SIV replication dramatically increased and then decreased in close inverse association with CD8 + T cell numbers: plasma viral loads (VLs) rebounded by nearly 4 logs at the CD8 + T cell nadir (day 10) before being brought back under nearly complete control by day 35 (Fig. 4a) . Although NK cells are also depleted by M-T807R1 mAb treatment, these cells are very few in number in LNs (Fig. 4c) , and in separate studies, we have noted that their efficient depletion by IL-15 blockade is not associated with enhanced SIV replication (A.A.O. and L.J.P., unpublished observation), observations that together strongly suggest that the rebound in SIV replication is related to loss of SIVspecific CD8 + T cells rather than NK cells. Prior to CD8 + lymphocyte depletion, replication-competent SIV was, as described above, highly restricted to the CD4 + T FH cell subset and levels of CD4 + T cell-associated SIV RNA (but not SIV DNA) was significantly higher in CD4 + T FH cells compared with CD4 + non-T FH memory cells in EC secondary lymphoid tissues (Fig. 4d-f and Supplementary Fig. 4) . However, at day 10 after CD8 + lymphocyte depletion, both the frequencies of cells harboring replication-competent SIV and cell-associated SIV RNA levels increased substantially in CD4 + non-T FH memory cells (~2 logs for cell-associated SIV RNA), whereas cell-associated SIV DNA levels increased only modestly (~ 1 log), data which taken together indicate a marked enhancement of productive infection within CD4 + non-T FH memory cells. CD8 + T cell recovery was associated with a progressive decline in the levels of both the frequencies of cells harboring replication-competent SIV and cell-associated SIV RNA levels in the non-T FH CD4 + memory T cells, with pre-depletion levels re-established in most monkeys by day 35 after depletion and all monkeys by days 84-136 after depletion (Fig. 4d-f and Supplementary Fig. 7) . Although CD8 + lymphocyte depletion also transiently increased levels of cell-associated SIV RNA in CD4 + T FH cells, the net effect of CD8 + T cell removal was an elimination or marked reduction of the pre-depletion disparity in levels of productive SIV infection between CD4 + T FH cells and CD4 + non-T FH memory cells. The loss of CD8 + T cells had the effect of transiently 'converting' ECs to TPs in terms of the distribution of productive infection between CD4 + T FH cells and non-T FH memory T cells. This transient equalization of productive SIV infection between CD4 + T FH cells and non-T FH memory cells after the CD8 + lymphocyte depletion was also observed within the spleen (Supplementary Fig. 7) , suggesting this was a general effect in all secondary lymphoid tissues.
CD8 + lymphocyte depletion has secondary effects on CD4 + memory T cell homeostasis, in particular the enhancement of CD4 + memory T cell proliferation 36 . To determine whether induction of homeostatic proliferation of non-T FH may have had a role in the CD8 ( Table 1 ). Light-colored lines, individual monkeys; bold diamonds, log median values of each group. Statistical analysis was performed as described in Figure 2d ; brackets indicate Wilcoxon signed-rank test; P < 0.05. Figure 5 The restriction of productive SIV infection to CD4 + T FH cells in EC LNs is not affected by activation of extrafollicular CD4 + memory T cells with IL-7 administration. Three EC monkeys that had recovered both CD8 + T cell counts and CD8 + T cell-mediated SIV control (plasma VL of <100 copies per milliliter) 5-6 months after CD8-specific antibody treatment were treated with recombinant rhesus IL-7 to activate extrafollicular CD4 + memory T cells. of recombinant IL-7 (30 µg kg −1 ) induced CD4 + non-T FH memory cell proliferation (%K i -67 + ) that was comparable to that induced by CD8 + lymphocyte depletion (Fig. 5a) . However, this treatment had no effect on the plasma VL or, most notably, on the highly restricted localization of replication-competent SIV to T FH cells in these EC monkeys (Fig. 5b,c) . Taken together, these data implicate the loss of CD8 + T cell-mediated anti-viral activity as the mechanism mediating transient equalization of productive SIV infection in CD4 + T FH and non-T FH memory cells after CD8 + lymphocyte depletion of EC monkeys, and in these monkeys, strongly suggest a differential ability of highly effective SIV-specific CD8 + T cells to clear productive SIV infection of CD4 + memory T cells within the T cell zones versus B follicles of secondary lymphoid tissues.
T FH cells preferentially harbor productive SIV infection after cART
The apparent ability of B follicular structures to substantially shield productively SIV-infected CD4 + T FH cells from CD8 + T cellmediated clearance raises the question of whether this mechanism might counter the ability of spontaneous or therapeutic vaccine-induced CD8 + T cell responses to eradicate or functionally cure HIV or SIV infection in the setting of effective pharmacologic viral suppression 6 . Given the data described above, we predict that if viral reactivation or residual viral replication occurs in CD4 + T FH cells within the secondary lymphoid tissues of individuals on cART, it would be relatively protected from clearance by such CD8 + T cell responses. Moreover, it is possible that even the conventional (less effective than EC) virus-specific CD8 + T cell responses present in typical individuals on cART might be able to generate sufficient CD8 + T cell-mediated immune pressure to restrict productive HIV or SIV infection arising from reactivation or residual replication in these individuals to the protected environment of the B cell follicle. To determine whether SIV reactivation or residual replication within CD4 + memory T cells was differentially distributed between the extrafollicular T cell zone and B cell follicles in the setting of pharmacologically suppressed SIV infection, we examined the levels of SIV RNA and DNA within CD4 + T FH cells and non-T FH memory cells from LN obtained from two independent cohorts of SIV-infected monkeys (Supplementary Table 2 ) that were treated with different cART regimens for at least 4 months, all with plasma VLs of <60 copies per milliliter at the time of testing (note that the level of productive SIV infection in these cART-suppressed monkeys was below the level of detection of our coculture assay). In cohort 1, LN and splenic CD4 + T FH and non-T FH memory cells were sorted on the basis of PD-1 and CD200 expression, as described above; in cohort 2, LN CD4 + T FH cells were sorted on the basis of expression of PD-1 and the follicular homing-associated chemokine receptor CXCR5 (which is also selectively expressed by Fig. 8 ). Cell-associated SIV RNA, but not SIV DNA, was significantly higher in CD4 + T FH cells compared with non-T FH memory cells in both cohorts, which is consistent with the preferential localization of residual productive SIV infection within the B cell follicles of secondary lymphoid tissues in the majority of cART-treated monkeys (Fig. 6a-c) . Although T FH cells constitute only a median of 12% of total CD4 + memory T cells within LNs of these cART-suppressed monkeys (Fig. 2a,b) , these data indicate that a substantial fraction of viral reactivation or residual viral replication in effectively cARTtreated monkeys occurs within the protected environment of the B cell follicle.
DISCUSSION
These studies indicate that in the absence of strong CD8 + T cell-mediated immune control-either typical progressive SIV infection or controlled SIV infection after CD8 + lymphocyte depletion-there are only minor differences in the levels of productive SIV infection between CD4 + T FH and non-T FH memory T cells; whereas in the presence of such control (particularly in elite control, defined here as plasma VL set points <6 × 10 2 SIV RNA copies per milliliter), there is marked restriction of productive SIV infection to CD4 + T FH cells by both phenotypic and anatomic criteria. Thus, for the first time, we directly demonstrate that CD8 + T cell-mediated control of SIV infection is linked to restriction in the anatomic location of productive infection, and that B cell follicles constitute a sanctuary for residual productive SIV infection in the face of highly effective CD8 + T cell responses. Although this novel immune avoidance mechanism is probably dispensable at the viral replication rates associated with untreated progressive infection, it becomes clinically relevant in elite control, in which it almost certainly has a major role in the persistence of productive infection. The ability of SIV to exploit the B follicular sanctuary to avoid highly effective CD8 + T cell effector responses constitutes a potentially important immune evasion strategy for the virus, because it provides for viral replication rates sufficient to allow for viral sequence evolution [10] [11] [12] and the possibility of eventual immune escape. In contrast, if highly effective virus-specific CD8 + T cell responses were able to drive the infection into full latency, such evolution and consequent escape could not occur.
In keeping with the general exclusion of most CD8 + T cells from B cell follicles 22, 23 , previous studies have established that in HIV or SIV infection, B cell follicles have reduced frequencies of HIV-and SIV-specific CD8 + T cells compared with extrafollicular sites [24] [25] [26] . Supplementary Fig. 1 ) from LN (a) and spleen (b) of 7 cohort 1 monkeys, which were chronically SIV mac251 -infected before cART treatment; Supplementary Table 2) . (c) Levels of cell-associated SIV RNA and DNA in sorted CD4 + memory T cell subsets (T CM and T Tr/EM cells versus T FH cells; Supplementary Fig. 8 ) from LN of ten cohort 2 monkeys, which were treated with cART 42 d after infection with SIV mac239 (Supplementary Table 2) . Light-colored lines, individual monkeys; bold diamonds, log median values of each group. Statistical analysis was performed as described in Figure 2d ; brackets indicate Wilcoxon signed-rank test, P < 0.05. 
r t i c l e s
This finding suggests that the B follicular sanctuary defined in this study might result from the normal physiologic regulation of follicular homing that limits CD8 + effector T cell migration into B cell follicles, thereby possibly compromising CD8 + T cell-mediated anti-viral activity in these structures. In addition, it is possible that the per cell anti-viral effector capabilities of the few CD8 + effector T cells that do enter the B cell follicle are less than those of their extrafollicular counterparts 38 , and/or that SIV-infected CD4 + T FH cells are more resistant to their effector activity. Notably, however, this shielding of SIV-infected cells within B cell follicles from CD8 + T cell effector function must be relative rather than absolute, as the transient increase in productively SIV-infected CD4 + T FH cells after CD8 + lymphocyte depletion (Fig. 4) indicates that CD4 + T FH cell infection is at least partially limited by effective CD8 + T cell responses. This control might result from distant effects of extrafollicular CD8 + T cells (potentially limiting entry of infected pre-T FH cells into the follicle), or to the few CD8 + T cells that gain follicular homing function 23, 38 . Notably, with progression of chronic HIV infection towards AIDS, increasing numbers of CD8 + T cells have been observed in B cell follicles [39] [40] [41] , as well as an expansion of CD8 + effector T cells expressing a CCR7 low CXCR5 high 'follicle homing' phenotype 42 . Thus, the normal relative exclusion of CD8 + effector T cells from B cell follicles is compromised during the transition from follicular hyperplasia to follicular lysis to, ultimately, the follicular involution and atrophy that characterizes progressive HIV disease 35 . However, the increased follicular localization of CD8 + T cells in this situation (progressive infection) occurs in the absence of effective anti-viral CD8 + T cell responses, and therefore probably contributes more to pathogenesis (inflammatory destruction of lymphoid architecture) than to viral control. Follicular integrity (operationally defined as the relative exclusion of CD8 + T cells from B cell follicles) is not compromised in elite control ( Fig. 3 and Supplementary Fig. 5) ; therefore, in this setting, follicular structure and/or the normal physiology of follicular migration would protect productively SIV-infected CD4 + T FH cells from CD8 + T cell-mediated clearance. Although our data do not definitively implicate the activity of SIV-specific CD8 + T cells in the preferential localization of SIV RNA to CD4 + T FH cells in monkeys with cART-suppressed infection, follicular integrity is largely intact in the LNs of these monkeys (Supplementary Fig. 9 ), and thus it is highly likely that the B cell follicle sanctuary operates in this setting as well (at least with cART initiation before the infection-associated destruction of LN architecture). It is generally accepted that eradication or functional cure of HIV or SIV infection will almost certainly require both the induction of latent virus and the immune-mediated destruction of the cells hosting the resultant viral reactivation 6, 43 . Given our observation that intrafollicular CD4 + T cells (T FH cells) comprise a substantial fraction of productively SIV-infected cells in the setting of cARTsuppressed infection, it is highly likely that the B cell follicle sanctuary will constitute a formidable barrier to the ability of spontaneous or vaccine-elicited CD8 + T cell responses to either clear viral reservoirs or fully suppress viral reactivation after cART cessation. Indeed, it might prove necessary to add a third component to HIV or SIV cure strategies that rely on CD8 + T cell responses to destroy HIV antigen + cells after latent virus reactivation: temporary disruption of B follicular integrity, perhaps using transient B cell depletion (for example, CD20-specific antibody therapy) or immunomodulation strategies (for example, CD40L blockade) 44 . Alternatively, it might be possible to develop vaccines or other immunotherapies that can generate CD8 + T cell effector responses that can efficiently penetrate and work within the B follicular environment 23, 38, 42 . In this regard, it is noteworthy that we have previously demonstrated one situation-prophylactic vaccination with CMV vectors expressing SIV proteins-in which a widely distributed, albeit very early, SIV infection can be cleared over time by an effector memory T cell-mediated mechanism 45 . In this situation, either the vaccine-generated SIV-specific effector memory T cell responses (which include both CD4 + and CD8 + components) were able to control infection before the seeding of CD4 + T FH cells into the B cell follicle, or these responses had an ability to penetrate B cell follicles and eliminate virally infected cells therein.
In conclusion, we have demonstrated that SIV can take advantage of the relative exclusion of CD8 + effector T cells from B cell follicles to persist and preferentially replicate within CD4 + T FH cells when CD8 + T cell-mediated immune pressure is high, thereby escaping even the highly potent CD8 + T cell responses that develop in EC. Because both follicular exclusion of human CD8 + T cells and the ability of human CD4 + T FH cells to support HIV infection are well documented 24, 29 , this mechanism is very likely to operate in HIV-infected humans as well. Therefore, therapies intended to eradicate HIV infection will almost certainly need to overcome the B follicular sanctuary.
METHODS
Methods and any associated references are available in the online version of the paper. The triple-stained sections were mounted in ProLong Gold antifade reagent (Life Technologies). All confocal images were acquired using a Leica TCS SP8 confocal microscope (Leica Microsystems) equipped with a 20×/NA 0.75 oil immersion objective. Large field images of the tissue sections were generated by assembly of numerous juxtaposed individual sub-images into a montage, assisted by Fiji software (http://fiji.sc/wiki/index.php/Fiji).
RNAscope analysis. We also used a next-generation, ultrasensitive RNA in situ hybridization technology, RNAscope (Advanced Cell Diagnostics), for SIV in situ hybridization, as previously described 49 . Quantification of the number of productively infected SIV RNA + cells either within or outside follicles was performed through manual counting of high magnification whole Aperio-scanned tissue sections using the Aperio elliptical annotation tool independently by three blinded individuals. Productively infected SIV RNA + cells were classified based on an intense centric SIV RNA signal within a single cell (both nuclear and cytoplasmic) that diffused toward the edges of the cell, which is distinguished from the 'lattice-like' filamentous pattern of extracellular FDC-bound virus that is seen within the follicles 31 . The average fraction of productively infected SIV RNA + cells within the B cell follicles is reported for EC and TP monkeys (total productively infected SIV RNA + cells counted: 245 for ECs, 1,252 for TPs). Table 2 all given as a single subcutaneous injection) and 600 mg darunavir twice daily boosted with 100 mg ritonavir twice daily (given orally in food). Daily darunavir and ritonavir (Oregon Health & Science University pharmacy) were stopped after 96 d. All cohort 2 monkeys had been infected with SIV mac239 before ART initiation at day 42 after infection and treated with cART for 26 weeks at the time of biopsy. The injectable component of the cART regimen was composed of 20 mg ml −1 TFV, 50 mg ml −1 FTC, and 2.5 mg ml −1 DTG in a solvent containing 25% (vol/vol) polyethylene glycol 400 (PEG-400), 15% (wt/vol) Captisol and 0.075 N sodium hydroxide (NaOH) in water. The injectable cART formulation was prepared by mixing DTG stock solution (10 mg ml −1 in PEG-400), TFV stock solution (80 mg ml −1 in 0.3 N NaOH), FTC stock solution (200 mg ml −1 in 0.3 N NaOH), and 30% (wt/wt) Captisol solution at a 1:1:2 (vol:vol:vol) ratio. The final solution had a pH ~6, was sterile-filtered, aliquotted into sterile glass vials and frozen at −20 °C until used. This injectable component of the cART regimen was administered subcutaneously once daily at 1 ml per kg of body weight.
Combination antiretroviral therapy (cART). For cohort 1 (Supplementary
Statistical analysis.
We conducted all statistical analyses without multiplicity correction, using nonparametric, two-sided tests 50 . Study animals were selected for inclusion in the study based on pre-specified criteria and these selected animals contributed data to all analyses. The only exceptions to this were instances when insufficient sorted cells could be recovered from available tissue samples, resulting in some variability in the group size across the various analyses. No statistical method was used to predetermine sample size. Because the animal groups were defined by controller status or ART status, no randomization was used, and no blinding was performed. To compare cell-associated viral DNA, RNA, or percentage of SIV-Gag p27 in CEMx174 within-animal differences across CD4 + memory subsets based on PD-1 and CD200 expression (PD-1 neg CD200 neg , PD-1 dim CD200 neg to dim , PD-1 high CD200 high ; Supplementary Fig. 1 ) or other differentiation markers (T CM , T Tr/EM , T FH cells; Supplementary Fig. 8 ), we conducted Friedman tests (non-parametric randomized block ANOVA) at the P = 0.05 significance level. For pairwise comparisons between categories of within-animal differences, we applied the Wilcoxon signed-rank test (at the P = 0.05 level). For comparisons across groups of animals we applied P = 0.05-level Kruskal-Wallis and Wilcoxon rank-sum tests (for > 2 and 2 groups, respectively). We used the R statistical computing language for all statistical analyses 51 . 
